In vitro study by Peter Mac showed INV043's effectiveness against six squamous cell carcinoma (SCC) cell lines that represent the full range of anal cancers. Most anal cancers are SCCs and are difficult to treat with the global market estimated to be worth US$1.3bn by 2028 (6.3% CAGR). The Peter Mac study added another clinically important class of tumours to the spectrum of other tumours already shown to be highly sensitive to INV043. Findings were consistent with the results of work done at the Hudson Institute on other cancer types. Preclinical testing using topical delivery of INV043 has now started as a prelude to moving to clinical human testing of anal SCC.
FULL ARTICLE
